25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 molecules and uses therefor
AssigneeMillennium Pharmaceuticals, Inc.
InventorsRachel E. Meyers, Mark J. Williamson
Life of this patent
Estimating the term…
Loading patent…
AssigneeMillennium Pharmaceuticals, Inc.
InventorsRachel E. Meyers, Mark J. Williamson
Estimating the term…
The invention provides isolated nucleic acids molecules, designated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 gene has been introduced or disrupted. The invention still further provides isolated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 proteins, fusion proteins, antigenic peptides and anti-25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
An isolated polypeptide comprising a polypeptide selected from the group consisting of:
An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:21.
An isolated polypeptide which is encoded by a nucleic acid molecule selected from the group consisting of the nucleotide sequence of SEQ ID NO:20 and SEQ ID NO:22.
Dependencies are inferred from the claim text.